What dose of Winstrol (stanozolol) do the label and trials give?
| Product | Strength and pack | Status |
|---|---|---|
| Winstrol, US12 | 2 mg tablet, bottles of 100 | Approval listed as withdrawn in a 2010 Federal Register notice |
| Stromba, UK and Ireland34 | 5 mg tablet | Discontinued; Irish licence withdrawn 29/07/2003 |
The former US Winstrol label, as RxList reproduces it, gives a starting dose of 2 mg three times a day for hereditary angioedema and, after a favorable initial response, reduces it at intervals of one to three months to a maintenance dosage of 2 mg a day.1
Which Winstrol tablets were supplied
The table is set at the top of the page
A search of DailyMed found no Winstrol label; the text here is RxList's 2021 reproduction.1
What the label says about dose
During the dose adjusting phase, the label calls for close monitoring of the patient's response, particularly if the patient has a history of airway involvement.1 It says some patients may be managed on a 2 mg alternate-day schedule.1 The label says dosage is individualized on the basis of the patient's clinical response, and that patients are placed on the lowest possible effective dose because anabolic steroids may cause serious adverse reactions, many of them dose related.1 The only indication the label states is prophylaxis of hereditary angioedema attacks.1
A search found no separate dose for men and women. For children, the label says long-term prophylactic therapy is generally not recommended, and that safety and efficacy in children with hereditary angioedema have not been established.1
What oral trials used
A search of ClinicalTrials.gov found no registered trial of stanozolol for bodybuilding or cycle use; the trials below were in hereditary angioedema, venous disease and urticaria, apart from a lipid study in 11 male weight lifters and a study in 3 healthy young men.56 In a 2007 report by Sloane and colleagues on hereditary angioedema patients treated for 20 to 40 years, the minimal initial effective dosage was 0.5 to 2.0 mg daily; treatment-related symptoms in 10 of 21 patients subsided with a dose reduction.7
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Sheffer, 1981 | 0.5 to 2 mg daily as the minimal effective dose; 4 mg a day judged unjustified for chronic therapy because of more frequent side effects8 | 27 patients with hereditary angioedema (12 male, 15 female) | 2 years |
| Sheffer, 1987 | 2 mg daily at first; after 2 months of control at that dose or at 1 mg a day, 4 mg every other day; then 2 or 1 mg every other day, with the interval widened to 1 week before stopping9 | Thirty-seven patients with hereditary angioedema | To 1986, when three were on daily, 18 on alternate-day and 16 on no maintenance |
| Carson, 2015 | Oral 2 mg twice daily plus leg compression, against leg compression alone (placebo)10 | 44 patients with lipodermatosclerosis and venous ulcers (21 active, 23 placebo) | Up to 6 months |
| McMullin, 1991 | 5 mg or a placebo tablet, given twice daily, with graduated compression stockings for all11 | Sixty patients with lipodermatosclerosis | 6 months |
| Parsad, 2001 | 2 mg twice daily with cetirizine 10 mg daily, against cetirizine 10 mg daily with placebo tablets twice daily12 | Fifty-eight patients with chronic refractory urticaria | 12 weeks |
| Thompson, 1989 | 6 mg a day by mouth, against intramuscular testosterone enanthate 200 mg a week, in a crossover design5 | 11 male weight lifters | Six weeks |
| Fryburg, 1997 | 0.1 mg/kg.day, route not stated6 | 3 of 5 healthy young men | 2 weeks |
Cycle length and schedule
A search of the label and PubMed found no cycle length for stanozolol: the label and hereditary angioedema studies describe continuous treatment stepped down.
Injectable stanozolol
The only human injectable dose in these sources is stanozolol 50 mg given intramuscularly 24 hours before surgery in patients at high risk of deep vein thrombosis, cited by Blamey and colleagues (1984) as their earlier finding; in their double-blind trial of sixty patients having elective abdominal surgery, scan-positive deep vein thrombosis occurred in 12 of 29 stanozolol patients (41%) and 11 of 31 placebo patients (35%), and the authors concluded that the regimen does not prevent postoperative deep vein thrombosis.13 The only injectable strength in these sources is a US veterinary suspension of 50 milligrams (mg) of stanozolol per milliliter, for dogs, cats and horses.14 The US veterinary regulation for stanozolol, 21 CFR 522.2150, gives deep intramuscular injection at weekly intervals: in the thigh for several weeks in dogs and cats, in the gluteal region for not more than 4 weeks in horses.14 With no human injectable strength found, no mg to mL conversion is given.
Storage
The label says to store the tablets at controlled room temperature 15° to 30° C (59° to 86° F), and gives no storage after opening.1 A search found no storage source or stability data for any injectable suspension.
Frequently asked questions
Does Winstrol need mixing or water?
The label describes Winstrol tablets for oral administration.1 A search of the label and PubMed found no water or mixing instruction.
What does the label say about the liver?
The label calls for periodic liver function tests because of hepatotoxicity of 17-alpha-alkylated androgens, and for periodic serum lipid and high-density lipoprotein cholesterol tests.1
Is Winstrol a controlled substance?
The label says Winstrol is a US Schedule III controlled substance.1
References
- RxList. Winstrol (Anabolic steroids): Side Effects, Uses, Dosage, Interactions, Warnings. 2021. rxlist.com
- Federal Register. Federal Register / Vol. 75, No. 139 / Wednesday, July 21, 2010 / Notices 42455. 2010. govinfo.gov
- NHS dm+d. Actual Medicinal Product (AMP) - Stromba 5mg tablets - dm+d browser. dmd-browser.nhsbsa.nhs.uk
- HPRA. Withdrawn medicines. hpra.ie
- PubMed. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. 1989. pubmed.ncbi.nlm.nih.gov
- PubMed. Short-term modulation of the androgen milieu alters pulsatile, but not exercise- or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes. 1997. pubmed.ncbi.nlm.nih.gov
- PubMed. Hereditary angioedema: Safety of long-term stanozolol therapy. 2007. pubmed.ncbi.nlm.nih.gov
- PubMed. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. 1981. pubmed.ncbi.nlm.nih.gov
- PubMed. Hereditary angioedema: a decade of management with stanozolol. 1987. pubmed.ncbi.nlm.nih.gov
- PubMed. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. 2015. pubmed.ncbi.nlm.nih.gov
- PubMed. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. 1991. pubmed.ncbi.nlm.nih.gov
- PubMed. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. 2001. pubmed.ncbi.nlm.nih.gov
- PubMed. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. 1984. pubmed.ncbi.nlm.nih.gov
- Cornell LII (21 CFR 522.2150). 21 CFR § 522.2150 - Stanozolol. law.cornell.edu